Non-melanoma skin cancer: new and future synthetic drug treatments

References

• Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. 1994 May;30(5 Pt 1):774–778.
   PubMed Web of Science ®Google Scholar
• Zloty D, Guenther LC, Sapijaszko M, et al. Non-melanoma skin cancer in Canada chapter 4: management of basal cell carcinoma. J Cutan Med Surg. 2015 May–Jun;19(3):239–248.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. Jama. 2005 Aug 10;294(6):681–690.
   PubMed Web of Science ®Google Scholar
• Soura E, Chasapi V, Stratigos AJ. Pharmacologic treatment options for advanced epithelial skin cancer. Expert Opin Pharmacother. 2015 Jul 3;16(10):1479–1493.
   PubMed Web of Science ®Google Scholar
• Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012 May;166(5):1069–1080.
   PubMed Web of Science ®Google Scholar
• Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist. 2010;15(12):1320–1328.
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN guidelines version 1. 2017 Basal Cell Skin Cancer 2016; [cited 2017 Jan 11]. Available from: http://www.nccn.org/
   Google Scholar
• Kaskel P, Lange U, Sander S, et al. Ultraviolet exposure and risk of melanoma and basal cell carcinoma in Ulm and Dresden, Germany. J Eur Acad Dermatol Venereol. 2015 Jan;29(1):134–142.
   PubMed Web of Science ®Google Scholar
• Kricker A, Armstrong BK, English DR, et al. A dose-response curve for sun exposure and basal cell carcinoma. Int J Cancer. 1995 Feb 8;60(4):482–488.
   PubMed Web of Science ®Google Scholar
• Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer–the role of sunlight. Adv Exp Med Biol. 2008;624:89–103.
   PubMed Web of Science ®Google Scholar
• Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med. 1992 Dec 3;327(23):1649–1662.
   PubMed Web of Science ®Google Scholar
• English DR, Armstrong BK, Kricker A, et al. Case-control study of sun exposure and squamous cell carcinoma of the skin. Int J Cancer. 1998 Jul 29;77(3):347–353.
   PubMed Web of Science ®Google Scholar
• Zanetti R, Rosso S, Martinez C, et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer. 2006 Mar 13;94(5):743–751.
   PubMed Web of Science ®Google Scholar
• Perkins JL, Liu Y, Mitby PA, et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2005 Jun 1;23(16):3733–3741.
   PubMed Web of Science ®Google Scholar
• Karagas MR, Nelson HH, Zens MS, et al. Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure. Epidemiology (Cambridge, Mass). 2007 Nov;18(6):776–784.
   PubMed Web of Science ®Google Scholar
• Watt TC, Inskip PD, Stratton K, et al. Radiation-related risk of basal cell carcinoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2012 Aug 22;104(16):1240–1250.
   PubMedGoogle Scholar
• Schwartz JL, Kopecky KJ, Mathes RW, et al. Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. Radiat Res. 2009 Feb;171(2):155–163.
   PubMed Web of Science ®Google Scholar
• Khalesi M, Whiteman DC, Tran B, et al. A meta-analysis of pigmentary characteristics, sun sensitivity, freckling and melanocytic nevi and risk of basal cell carcinoma of the skin. Cancer Epidemiol. 2013 Oct;37(5):534–543.
   PubMed Web of Science ®Google Scholar
• Bernat Garcia J, Morales Suarez-Varela M, Vilata JJ, et al. Risk factors for non-melanoma skin cancer in kidney transplant patients in a Spanish population in the Mediterranean region. Acta Derm Venereol. 2013 Jul 6;93(4):422–427.
   PubMed Web of Science ®Google Scholar
• Zilinska Z, Sersenova M, Chrastina M, et al. Occurrence of malignancies after kidney transplantation in adults: Slovak multicenter experience. Neoplasma. 2017 Jan 5;64(2):311–317.
   PubMedGoogle Scholar
• Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000 Dec;136(12):1524–1530.
   PubMedGoogle Scholar
• Dubin N, Kopf AW. Multivariate risk score for recurrence of cutaneous basal cell carcinomas. Arch Dermatol. 1983 May;119(5):373–377.
   PubMedGoogle Scholar
• Bogelund FS, Philipsen PA, Gniadecki R. Factors affecting the recurrence rate of basal cell carcinoma. Acta Derm Venereol. 2007;87(4):330–334.
   PubMed Web of Science ®Google Scholar
• McCusker M, Basset-Seguin N, Dummer R, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer. 2014 Mar;50(4):774–783.
   PubMed Web of Science ®Google Scholar
• Parren LJ, Frank J. Hereditary tumour syndromes featuring basal cell carcinomas. Br J Dermatol. 2011 Jul;165(1):30–34.
   PubMed Web of Science ®Google Scholar
• Bath-Hextall F, Bong J, Perkins W, et al. Interventions for basal cell carcinoma of the skin: systematic review. BMJ (Clin Res Ed). 2004 Sep 25; 329(7468):705.
   PubMed Web of Science ®Google Scholar
• Bath-Hextall FJ, Perkins W, Bong J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007 Jan 24;(1):Cd003412.
   PubMed Web of Science ®Google Scholar
• Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989 Mar;15(3):315–328.
   PubMedGoogle Scholar
• Smeets NW, Krekels GA, Ostertag JU, et al. Surgical excision vs Mohs’ micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet (London, England). 2004 Nov 13-19;364(9447):1766–1772.
   PubMed Web of Science ®Google Scholar
• Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature. 1980 Nov 30;287(5785):795–801.
   PubMed Web of Science ®Google Scholar
• Evangelista M, Tian H, De Sauvage FJ. The Hedgehog signaling pathway in cancer. Clin Cancer Res. 2006;12(20):5924–5928.
   PubMed Web of Science ®Google Scholar
• Scales SJ, De Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009;30(6):303–312.
   PubMed Web of Science ®Google Scholar
• Katoh Y, Katoh M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med. 2009 Sep;9(7):873–886.
   PubMed Web of Science ®Google Scholar
• Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003 Oct 23;425(6960):846–851.
   PubMed Web of Science ®Google Scholar
• Thayer SP, Di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003 Oct 23;425(6960):851–856.
   PubMed Web of Science ®Google Scholar
• Hahn H, Wicking C, Zaphiropoulos PG, et al. Mutations of the human homolog of drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85(6):841–851.
   PubMed Web of Science ®Google Scholar
• Ingham PW, Placzek M. Orchestrating ontogenesis: variations on a theme by sonic Hedgehog. Nat Rev Genet. 2006 11;7(11):841–850.
   PubMed Web of Science ®Google Scholar
• Izzi L, Lévesque M, Morin S, et al. Boc and Gas1 each form distinct shh receptor complexes with Ptch1 and are required for shh-mediated cell proliferation. Developmental Cell. 2011;20(6):788–801.
   PubMed Web of Science ®Google Scholar
• Myers BR, Sever N, Chong YC, et al. Hedgehog pathway modulation by multiple lipid binding sites on the smoothened effector of signal response. Developmental Cell. 2013;26(4):346–357.
   PubMed Web of Science ®Google Scholar
• Aberger F, Ruiz IAA. Context-dependent signal integration by the GLI code: the oncogenic load, pathways, modifiers and implications for cancer therapy. Semin Cell Dev Biol. 2014 Sep;33:93–104.
   PubMed Web of Science ®Google Scholar
• Humke EW, Dorn KV, Milenkovic L, et al. The output of Hedgehog signaling is controlled by the dynamic association between suppressor of fused and the gli proteins. Genes Dev. 2010 Apr 1;24(7):670–682.
   PubMed Web of Science ®Google Scholar
• Wang B, Fallon JF, Beachy PA. Hedgehog-regulated processing of Gli3 produces an anterior/posterior repressor gradient in the developing vertebrate limb. Cell. 2000 Feb 18;100(4):423–434.
   PubMed Web of Science ®Google Scholar
• Bowers M, Eng L, Lao Z, et al. Limb anterior-posterior polarity integrates activator and repressor functions of GLI2 as well as GLI3. Dev Biol. 2012 Oct 1;370(1):110–124.
   PubMed Web of Science ®Google Scholar
• Liu J, Heydeck W, Zeng H, et al. Dual function of suppressor of fused in Hh pathway activation and mouse spinal cord patterning. Dev Biol. 2012 Feb 15;362(2):141–153.
   PubMed Web of Science ®Google Scholar
• Svärd J, Henricson KH, Persson-Lek M, et al. Genetic elimination of suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway. Developmental Cell. 2006;10(2):187–197.
   PubMed Web of Science ®Google Scholar
• Epstein EH. Basal cell carcinomas: attack of the Hedgehog. Nat Rev Cancer. 2008 Oct;8(10):743–754.
   PubMed Web of Science ®Google Scholar
• Xie J, Murone M, Luoh SM, et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature. 1998 Jan 1;391(6662):90–92.
   PubMed Web of Science ®Google Scholar
• High A, Zedan W. Basal cell nevus syndrome. Curr Opin Oncol. 2005 Mar;17(2):160–166.
   PubMed Web of Science ®Google Scholar
• Muller EA, Aradhya S, Atkin JF, et al. Microdeletion 9q22.3 syndrome includes metopic craniosynostosis, hydrocephalus, macrosomia, and developmental delay. Am J Med Genet Part A. 2012 Feb;158a(2):391–399.
   PubMed Web of Science ®Google Scholar
• Bonilla X, Parmentier L, King B, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet. 2016 Apr;48(4):398–406.
   PubMed Web of Science ®Google Scholar
• Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449-a potent inhibitor of the Hedgehog pathway. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5576–5581.
   PubMed Web of Science ®Google Scholar
• FDA - ERIVEDGE® Prescribing Information. [cited 2017 Jan]. Available from: http://wwwaccessdatafdagov/drugsatfda_docs/label/2012/203388lblpdf
   Google Scholar
• EMA - European public assessment report (EPAR) for Erivedge®. [cited 2017 Jan]. Available from: http://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002602/WC500146820pdf
   Google Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 7;366(23):2171–2179.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164–1172.
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of Hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011 Apr 15;17(8):2502–2511.
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Lewis K, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun;72(6):1021–6.e8.
   PubMed Web of Science ®Google Scholar
• Grob JJ, Kunstfeld R, Dreno B, et al. Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients. J Clin Oncol. 2013;31(suppl; abstr 9036).
   Google Scholar
• Basset-Seguin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015 Jun;16(6):729–736.
   PubMed Web of Science ®Google Scholar
• Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014 Jan;70(1):60–69.
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Tang JY, Rogers GS, et al. The RegiSONIC disease registry: preliminary effectiveness and safety in the first 66 newly diagnosed locally advanced basal cell carcinoma (BCC) patients treated with vismodegib. J Clin Oncol. 2015;33(suppl; abstr 9023).
   Google Scholar
• Tan JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the Hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012 Jun 7;366(23):2180–2188.
   PubMed Web of Science ®Google Scholar
• Rogers G, Kunstfeld R, Schadendorf D, et al. Mikie: A randomized, double-blinded, regimen-controlled, phase 2 study to assess the efficacy and safety of two different vismodegib (VISMO) regimens in patients (pts) with multiple basal cell carcinomas (BCCs). J Clin Oncol. 2016;34(suppl; abstr 9509).
   Google Scholar
• Ally MS, Aasi S, Wysong A, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014 Nov;71(5):904–11.e1.
   PubMed Web of Science ®Google Scholar
• Basset-Seguin N, Dupuy A, Saiag P, et al. VISMONEO - a phase II study assessing vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma - Patients characteristics. Ann Oncol. 2016;27(suppl_6):1155P–55P.
   Google Scholar
• Leiter U, Hillen U, Gutzmer R, et al. A phase II, single-armed, multicenter trial of neoadjuvant vismodegib in patients with large and/or recurrent basal cell carcinoma: NICCI. J Clin Oncol. 2014;32(5s). (suppl; abstr TPS9116^).
   Google Scholar
• FDA - ODOMZO® Prescribing Information. [cited 2017 Jan]. Available from: http://wwwaccessdatafdagov/drugsatfda_docs/label/2015/205266s000lblpdf
   Google Scholar
• EMA - European public assessment report (EPAR) for Odomzo®. [cited 2017 Jan]. Available from: http://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002839/WC500192972pdf
   Google Scholar
• Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun;16(6):716–728.
   PubMed Web of Science ®Google Scholar
• Rodon J, Tawbi HA, Thomas AL, et al. A Phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014;20(7):1900–1909.
   PubMed Web of Science ®Google Scholar
• Dummer R, Guminski A, Gutzmer R, et al. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 7;75(1):113–25.e5.
   PubMed Web of Science ®Google Scholar
• Dummer R, Migden MR, Guminski A, et al. Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis. J Clin Oncol. 2016;34(suppl; abstr 9538).
   PubMed Web of Science ®Google Scholar
• Brinkhuizen T, Reinders MG, Van Geel M, et al. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. J Am Acad Dermatol. 2014 Nov;71(5):1005–1008.
   PubMed Web of Science ®Google Scholar
• Pricl S, Cortelazzi B, Dal Col V, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015 Feb;9(2):389–397.
   PubMed Web of Science ®Google Scholar
• Danial C, Sarin KY, Oro AE, et al. An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib. Clin Cancer Res. 2016 Mar 15;22(6):1325–1329.
   PubMed Web of Science ®Google Scholar
• Jacobsen AA, Aldahan AS, Hughes OB, et al. Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies. JAMA Dermatol. 2016 Jul 1;152(7):816–824.
   PubMed Web of Science ®Google Scholar
• Pfeiffer P, Hansen O, Rose C. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. Eur J Cancer. 1990 Jan;26(1):73–77.
   PubMed Web of Science ®Google Scholar
• Carneiro BA, Watkin WG, Mehta UK, et al. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest. 2006 Jun-Jul;24(4):396–400.
   PubMed Web of Science ®Google Scholar
• Khandekar JD. Complete response of metastatic basal cell carcinoma to cisplatin chemotherapy: a report on two patients. Arch Dermatol. 1990 Dec;126(12):1660.
   PubMedGoogle Scholar
• Wysong A, Aasi SZ, Tang JY. Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. JAMA Dermatol. 2013 May;149(5):615–616.
   PubMed Web of Science ®Google Scholar
• Espeli V, Ruegg E, Hottinger AF, et al. Weekly multi-agent chemotherapy (CMF-b) for advanced non-melanoma skin cancer. Anticancer Res. 2016 May;36(5):2359–2364.
   PubMed Web of Science ®Google Scholar
• Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory Phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32(8):745–751.
   PubMed Web of Science ®Google Scholar
• Chen B, Trang V, Lee A, et al. Posaconazole, a second-generation triazole antifungal drug, inhibits the Hedgehog signaling pathway and progression of basal cell carcinoma. Mol Cancer Ther. 2016 May;15(5):866–876.
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Messersmith WA, Shaik MN, et al. A phase I study of PF-04449913, an oral Hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 1;21(5):1044–1051.
   PubMed Web of Science ®Google Scholar
• Jimeno A, Weiss GJ, Miller WH Jr., et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res. 2013 May 15;19(10):2766–2774.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Jan]. Available from: https://wwwcancergov/about-cancer/treatment/clinical-trials/search/printresults?cid=266929&protocolsearchid=15470903
   Google Scholar
• English DR, Armstrong BK, Kricker A, et al. Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a case-control study. Int J Cancer. 1998 May 29;76(5):628–634.
   PubMed Web of Science ®Google Scholar
• Karagas MR, Nelson HH, Sehr P, et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst. 2006 Mar 15;98(6):389–395.
   PubMed Web of Science ®Google Scholar
• Patel AS, Karagas MR, Perry AE, et al. Exposure profiles and human papillomavirus infection in skin cancer: an analysis of 25 genus beta-types in a population-based study. J Invest Dermatol. 2008 Dec;128(12):2888–2893.
   PubMed Web of Science ®Google Scholar
• Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005 Mar 16;97(6):425–432.
   PubMed Web of Science ®Google Scholar
• Ping XL, Ratner D, Zhang H, et al. PTCH mutations in squamous cell carcinoma of the skin. J Invest Dermatol. 2001 Apr;116(4):614–616.
   PubMed Web of Science ®Google Scholar
• Kao GF. Carcinoma arising in Bowen’s disease. Arch Dermatol. 1986 Oct;122(10):1124–1126.
   PubMedGoogle Scholar
• Nikolaou V, Stratigos AJ, Tsao H. Hereditary nonmelanoma skin cancer. Semin Cutan Med Surg. 2012;31(4):204–210.
   PubMed Web of Science ®Google Scholar
• Brantsch KD, Meisner C, Schonfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008 Aug;9(8):713–720.
   PubMed Web of Science ®Google Scholar
• Cherpelis BS, Marcusen C, Lang PG. Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg. 2002 Mar;28(3):268–273.
   PubMed Web of Science ®Google Scholar
• Lansbury L, Leonardi-Bee J, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin. Cochrane Database Syst Rev. 2010 Apr;14(4):Cd007869.
   Google Scholar
• Lansbury L, Bath-Hextall F, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ (Clin Res Ed). 2013 Nov 4;347:f6153.
   PubMed Web of Science ®Google Scholar
• Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992 Jun;26(6):976–990.
   PubMed Web of Science ®Google Scholar
• Karagas MR, Stukel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. Jama. 1992 Jun 24;267(24):3305–3310.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem. 1988;57:443–478.
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995 7;19(3):183–232.
   PubMed Web of Science ®Google Scholar
• Krähn G, Leiter U, Kaskel P, et al. Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. Eur J Cancer. 2001 1;37(2):251–259.
   PubMed Web of Science ®Google Scholar
• Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol. 2007 Jul;143(7):889–892.
   PubMedGoogle Scholar
• Arnold AW, Bruckner-Tuderman L, Zuger C, et al. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology (Basel, Switzerland). 2009;219(1):80–83.
   PubMed Web of Science ®Google Scholar
• Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011 Sep 1;29(25):3419–3426.
   PubMed Web of Science ®Google Scholar
• Reigneau M, Robert C, Routier E, et al. Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas. Br J Dermatol. 2015 Aug;173(2):527–534.
   PubMed Web of Science ®Google Scholar
• Mesia R, Henke M, Fortin A, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015 Feb;16(2):208–220.
   PubMed Web of Science ®Google Scholar
• Giralt J, Trigo J, Nuyts S, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015 Feb;16(2):221–232.
   PubMed Web of Science ®Google Scholar
• Foote MC, McGrath M, Guminski A, et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol. 2014 Oct;25(10):2047–2052.
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003 May 15;21(10):1980–1987.
   PubMed Web of Science ®Google Scholar
• Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009 Apr 10;27(11):1864–1871.
   PubMed Web of Science ®Google Scholar
• Perez CA, Song H, Raez LE, et al. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2012 Sep;48(9):887–892.
   PubMed Web of Science ®Google Scholar
• Lewis CM, Glisson BS, Feng L, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Mar 1;18(5):1435–1446.
   PubMed Web of Science ®Google Scholar
• Heath CH, Deep NL, Nabell L, et al. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1275–1281.
   PubMed Web of Science ®Google Scholar
• Engelhardt C, Curiel-Lewandrowski C, Warneke J, et al. Metastatic cutaneous squamous cell carcinoma responding to erlotinib therapy. J Am Acad Dermatol. 2011 7;65(1):237–238.
   PubMed Web of Science ®Google Scholar
• Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin. [cited 2017 Jan]. Available from: https://clinicaltrialsgov/show/NCT01059305
   Google Scholar
• Sadek H, Azli N, Wendling JL, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer. 1990 Oct 15;66(8):1692–1696.
   PubMed Web of Science ®Google Scholar
• Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst. 1992 Feb 19;84(4):235–241.
   PubMedGoogle Scholar
• Borradori L, Sutton B, Shayesteh P, et al. Rescue therapy with anti-programmed cell death protein 1 inhibitors (PD-1) of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in 5 cases. Br J Dermatol. 2016 175(6):1382–1386.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Jan]. Available from: https://wwwcancergov/about-cancer/treatment/clinical-trials/search/r?t=C4819%7Cskin_squamous_cell_carcinoma&z=&a=
   Google Scholar